Non-Vitamin K Antagonist Oral Anticoagulants in Medical Conditions at High Risk of Thromboembolism beyond Atrial Fibrillation
Keun-Sik Hong
J Stroke. 2019;21(3):259-275.   Published online 2019 Sep 30     DOI:
Citations to this article as recorded by Crossref logo
Use of Non-Vitamin K Dependent Oral Anticoagulant in Ischemic Stroke
Hyungjong Park, Joonsang Yoo
Journal of the Korean Neurological Association.2022; 40(1): 1.     CrossRef
Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line Chemotherapy
Aristotelis Bamias, Kimon Tzannis, Ioannis Dimitriadis, Georgios Tsironis, Alkistis-Maria Papatheorodidi, Anna Tsiara, Charalampos Fragkoulis, Aikaterini Xirokosta, Despoina Barbarousi, Georgios Papadopoulos, Roubini Zakopoulou, Ioannis Varkarakis, Irakli
Clinical Genitourinary Cancer.2020;[Epub]     CrossRef
A case-report of two patients with hereditary protein S deficiency treated by rivaroxaban
Jianyao Lou, Li Yin, Xueying Ke, Liang Zhang, Fangfang Xu, Zhenjie Liu
Blood Coagulation & Fibrinolysis.2020; 31(6): 405.     CrossRef
Tackling Nonatrial Fibrillation Diseases Using Nonvitamin K Antagonist Oral Anticoagulant: by What and for Whom?
Jong S. Kim
Journal of Stroke.2019; 21(3): 241.     CrossRef